Severity: 8192
Message: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated
Filename: helpers/my_audit_helper.php
Line Number: 8900
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 8900
Function: str_replace
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3362
Function: formatAIDetailSummary
File: /var/www/html/application/controllers/Search.php
Line: 168
Function: pubMedSearch_Global
File: /var/www/html/index.php
Line: 316
Function: require_once
Severity: 8192
Message: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated
Filename: helpers/my_audit_helper.php
Line Number: 8900
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 8900
Function: str_replace
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3362
Function: formatAIDetailSummary
File: /var/www/html/application/controllers/Search.php
Line: 168
Function: pubMedSearch_Global
File: /var/www/html/index.php
Line: 316
Function: require_once
Severity: 8192
Message: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated
Filename: helpers/my_audit_helper.php
Line Number: 8900
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 8900
Function: str_replace
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3362
Function: formatAIDetailSummary
File: /var/www/html/application/controllers/Search.php
Line: 168
Function: pubMedSearch_Global
File: /var/www/html/index.php
Line: 316
Function: require_once
2,082 results match your criteria: "The Sanofi-Genzyme R&D Center[Affiliation]"
Mult Scler
December 2024
Neurology Unit and Multiple Sclerosis Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Eur J Cancer
January 2025
Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. Electronic address:
Background: Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing anti-tumor treatment is through the modulation of coagulation and platelet activity. Both have been found to play an important role in the tumor microenvironment, tumor growth and metastasis.
View Article and Find Full Text PDFEur J Neurol
January 2025
Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Cancer Med
December 2024
Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Background: There has been a paradoxical rise in young-onset gastric cancer (YOGC), defined as gastric cancer (GC) diagnosed before age 50. Precursor lesions may contribute to pathogenesis, though their role in progression to different histologic subtypes is unclear. The impact of self-reported race is also poorly characterized and may be unreliable as a proxy for genetic differences.
View Article and Find Full Text PDFTher Adv Hematol
December 2024
Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Venusberg Campus 1, Gebäude 43, Bonn 53127, Germany.
Background: Although hemophilia A mainly affects males, carriers (defined as females with hemophilia A, as well as symptomatic or asymptomatic hemophilia A carriers) are at risk of excessive bleeding, particularly during trauma or during surgical procedures. Clinical trials have focused on male patients with severe disease, and data for females are limited. Improved, evidence-based treatment guidelines for management of hemophilia A carriers are required.
View Article and Find Full Text PDFNeurology
December 2024
From the Department of Neurology (P.D.C., S.S.), and Department of Biostatistics & Informatics (S.S.), University of Colorado Anschutz Medical Campus; University of Colorado School of Medicine Anschutz Medical Campus (R.D., P.W., E.E., B.V., E.M., K.V.N., A.M.C., A.L.P.); University of Colorado School of Medicine (R.F.), Aurora; School of Osteopathic Medicine (R.F.), Kanas City University, MO; University of Colorado School of Medicine Anschutz Medical Campus (R.V.C.); School of Medicine (R.V.C.), Aurora, CO; Renown Health (R.V.C.), Reno, NV; Rocky Mountain MS Center (K.V.N., A.L.P.), University of Colorado School of Medicine; and Skaggs School of Pharmacy and Pharmaceutical Sciences (K.V.N.), University of Colorado Anschutz Medical Campus, Aurora.
Neurologist
January 2025
Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA.
Objectives: To assess characteristics of increased intracranial pressure (ICP) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Methods: This is a multicenter retrospective review of 84 MOGAD cases at the University of Florida, Baylor College of Medicine, the University of California San Diego, and Providence Health and Services, Portland, Oregon, to identify cases with a documented increased opening pressure >25 cm H2O. A literature review was conducted to identify previously reported MOGAD cases with an opening pressure >25 cm H2O.
Mult Scler
December 2024
Univ Rennes, EHESP, CNRS, Inserm, Arènes-UMR 6051, RSMS (Recherche sur les Services et Management en Santé)-U 1309, Rennes, France.
Background: We hypothesized that differences in access to disease-modifying treatments (DMTs) could explain the association between socioeconomic status and disability progression in multiple sclerosis (MS).
Objective: This study aimed to analyze the association between education level and DMT use in France.
Methods: All patients from OFSEP network with MS onset over 1996-2014 and aged ⩾ 25 years at onset were included.
J Thromb Haemost
November 2024
Medicarte IPS, National Comprehensive Hemophilia Treatment Center, Medellin, Colombia.
Recently, the International Society on Thrombosis and Haemostasis (ISTH) Hemophilia Guidelines were published in this journal. The authors of these guidelines should be commended for a herculean task that took years to complete, and while this is no doubt a welcome addition to the literature, it does leave many questions for the clinician. This is primarily because 11 of the 13 recommendations are conditional, essentially meaning "that clinicians and patients need to consider individual preferences as well as the specific circumstances in which the decision is being made for implementation of the recommendation.
View Article and Find Full Text PDFCancer
January 2025
Department of Urology, University of California San Diego, La Jolla, California, USA.
Mult Scler
November 2024
Univ Rennes, EHESP, CNRS, Inserm, Arènes-UMR 6051, RSMS (Recherche sur les Services et Management en Santé)-U 1309, Rennes, France.
Background: Studies have reported an association between socioeconomic status and disability progression in multiple sclerosis (MS), but findings using the pre-MS individual socioeconomic status are missing.
Objective: The objective was to investigate the association between education level and disability progression.
Methods: All Observatoire Français de la Sclérose en Plaques (OFSEP) patients with MS clinical onset over 1960-2014, and aged ⩾25 years at MS onset were included.
Brain Commun
November 2024
Division of Neurology, University of British Columbia, Vancouver, Canada V6T 2B5.
Spinal cord disease is important in most people with multiple sclerosis, but assessment remains less emphasized in patient care, basic and clinical research and therapeutic trials. The North American Imaging in Multiple Sclerosis Spinal Cord Interest Group was formed to determine and present the contemporary landscape of multiple sclerosis spinal cord evaluation, further existing and advanced spinal cord imaging techniques, and foster collaborative work. Important themes arose: (i) multiple sclerosis spinal cord lesions (differential diagnosis, association with clinical course); (ii) spinal cord radiological-pathological associations; (iii) 'critical' spinal cord lesions; (iv) multiple sclerosis topographical model; (v) spinal cord atrophy; and (vi) automated and special imaging techniques.
View Article and Find Full Text PDFFront Immunol
November 2024
Immunology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Objective: To ascertain the changes of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) values in relapsing-remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and their association with treatment response.
Methods: Multicenter prospective study including 115 RRMS patients initiating ocrelizumab treatment between February 2020 and March 2022 followed during a year. Serum samples were collected at baseline and every 3 months to measure sNfL and sGFAP levels using single-molecule array (SIMOA) technology.
Allergol Select
November 2024
Institute of Allergology, Charité Universitätsmedizin Berlin und Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin.
Pharmacoepidemiol Drug Saf
December 2024
Department of Medicine, Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Neurol Sci
November 2024
Department of NEUROFARBA, University of Florence, Largo Piero Palagi, 1, Florence, 50139, Italy.
Objective: Cognitive impairment affects approximately 30% of pediatric onset Multiple Sclerosis (POMS) patients with a negative impact on everyday life. The aim of this study was to evaluate the feasibility and effectiveness of a home-based, computer-assisted training of attention in patients with POMS.
Methods: This was a randomized double-blind study.
Front Neurol
November 2024
Department of Neurosciences, University of Padua, Padova, Italy.
Am J Hum Genet
December 2024
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:
J Allergy Clin Immunol
January 2025
Los Altos, Calif.
Asthma has been increasingly recognized as a heterogeneous disease; however, many patients with asthma have allergic asthma (AA). Inhaled corticosteroids and other inhalers have been integral in treating many symptoms of asthma, but these medications do not completely address the disease's underlying mechanism. Pediatric asthma imposes a substantial burden on patients and the health care system.
View Article and Find Full Text PDFActas Dermosifiliogr
November 2024
Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, España; Departament de Medicina, Universitat Autònoma de Barcelona (UAB), Barcelona, España.
Res Involv Engagem
November 2024
Allergy & Asthma Network, 10304 Eaton Place, Suite 100, Fairfax, VA, 22030, USA.
Background: Inequity in asthma and COVID-19 outcomes and research among Hispanic or Latino individuals is well established. Patient centered outcomes research (PCOR) may help address these inequalities. This report describes the development, implementation, and evaluation of a virtual conference series program titled "Unidos Hablemos de/United, Let's Talk About" intended to address the health literacy of the Hispanic/Latino community regarding asthma and COVID-19 and to encourage involvement in PCOR.
View Article and Find Full Text PDFBMC Cancer
November 2024
Department of Dermatology, University of Kiel, Kiel, Germany.
Background: Following the pivotal phase II trial BOLT, the Hedgehog (Hh) inhibitor sonidegib was approved in the EU to treat locally advanced basal cell carcinoma (laBCC) in patients not amenable to surgery or radiotherapy. We report safety data from the interim analysis of the real-world NISSO study.
Methods: NISSO is an ongoing non-interventional, multinational, post-authorization safety study (NCT04066504).
J Patient Rep Outcomes
November 2024
ERN-NMD Center for Neuromuscular Disorders of Messina, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Dermatol Ther (Heidelb)
December 2024
Oregon Health and Science University, Portland, USA.
Purpose: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL.
Patients And Methods: Patients included those with CD30 expression in ≥1% of tumor cells and who were R/R following ≥1 prior line of systemic therapy.